

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Sequencing SARS-CoV-2 from Antigen Tests

Ashley Nazario-Toole^{1¶}, Holly M. Nguyen^{1¶}, Hui Xia¹, Dianne N. Franke^{2,3}, John W. Kieffer^{2,3},
and Thomas F. Gibbons^{1*}

¹ 59th Medical Wing, Clinical Investigations and Research Support Laboratory, Joint Base San Antonio-Lackland, TX, USA

² Trainee Health Surveillance, 559th Medical Group, THLS, Joint Base San Antonio-Lackland, TX, USA

³ Trainee Health, 559th Medical Group, THLS, Joint Base San Antonio-Lackland, TX, USA

* Corresponding author: thomas.f.gibbons6.civ@mail.mil (TG)

¶ These authors contributed equally to this work.

Disclaimer: The views expressed are those of the author and are not necessarily the official views of, or endorsed by, the U.S. Government, the Department of Defense, or the Department of the Air Force. No Federal endorsement of the platforms to produce this research data is intended. The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DoDI 3216.02_AFI 40-402.

26 **Abstract**

27 Genomic surveillance empowers agile responses to SARS-CoV-2 by enabling scientists and
28 public health analysts to issue recommendations aimed at slowing transmission, prioritizing
29 contact tracing, and building a robust genomic sequencing surveillance strategy. Since the start
30 of the pandemic, real time RT-PCR diagnostic testing from upper respiratory specimens, such as
31 nasopharyngeal (NP) swabs, has been the standard. Moreover, respiratory samples in viral
32 transport media are the ideal specimen for SARS-CoV-2 whole-genome sequencing (WGS). In
33 early 2021, many clinicians transitioned to antigen-based SARS-CoV-2 detection tests, which use
34 anterior nasal swabs for SARS-CoV-2 antigen detection. Despite this shift in testing methods, the
35 need for whole-genome sequence surveillance remains. Thus, we developed a workflow for
36 whole-genome sequencing with antigen test-derived swabs as an input rather than
37 nasopharyngeal swabs. In this study, we use excess clinical specimens processed using the
38 BinaxNOW™ COVID-19 Ag Card. We demonstrate that whole-genome sequencing from antigen
39 tests is feasible and yields similar results from RT-PCR-based assays utilizing a swab in viral
40 transport media.

41 **Introduction**

42 Early in the pandemic Mercatelli and Giorgi predicted a low mutation rate for SARS-CoV-2 based
43 on whole-genome sequencing of 48,635 specimens [1]. Continued genomic surveillance has
44 revealed a worrying mutation rate of 3.7×10^{-6} per nucleotide per cycle [2]. Furthermore, the rate
45 of mutation varies across the SARS-CoV-2 genome, with several sites exhibiting recurrent
46 mutations that, due to strong positive selection, emerged independently a minimum of three times
47 in strains sequenced across the globe [3]. Ongoing genomic surveillance of SARS-CoV-2 is
48 critical for identifying emerging variants [4,5]; driving changes to public health policies [6]; and
49 confirming cases of reinfection [7].

50 **Variants**

51 The CDC defines a variant as a viral genome that has one or more mutations that differentiate it
52 from other variants in circulation [8]. Variants may have different potential impacts on public
53 health. Variants of interest (VOIs) require monitoring. Variants of concern (VOCs) may affect
54 treatment, transmission, or disease severity. Variants of high consequence (VOHC) have
55 significantly reduced effectiveness of prevention measures or therapeutics relative to existing or
56 previous variants. Fortunately, no VOHCs have been identified to date. The following VOCs
57 highlight the challenges faced by clinicians and public health officials: B.1.1.7 (UK) increased
58 transmission, P.1 (Brazilian) reduced serum neutralization, and B.1.351 (South African) reduced
59 vaccine efficacy in clinical trials conducted by Pfizer and Novavax [9–12]. Increased transmission
60 of regional strain variants may prompt enacting or increasing social distancing, mask wearing,
61 and/or travel restriction.

62 **Reinfection**

63 Although exceedingly rare, reinfection has been documented and is a threat to vulnerable
64 populations. Although most suspected cases of reinfection were a resurgence of the same viral
65 strain that initially infected the patient, other cases demonstrate reinfection with genetically distinct
66 genomes [7,13]. Genome surveillance enables us to monitor for cases of reinfection and discern
67 whether these cases are associated with particular variants.

68 **Specimen Sources**

69 Initially, SARS-CoV-2 tests relied on nasopharyngeal swabs placed in viral transport media (VTM)
70 followed by RT-PCR [14–16]. In May 2020, the FDA approved the first emergency use
71 authorization for an antigen test of SARS-CoV-2 [17]. In early 2021, the DoD began using antigen
72 testing on asymptomatic active duty and DoD civilian personnel [18,19]. Antigen tests meet the
73 World Health Organization's (WHO) definition of an Affordable, Selective and Sensitive, User-

74 friendly, Rapid and Robust, Equipment-free, Deliverable to end-users (ASSURED) diagnostic
75 tool [20,21]. Thus, antigen testing has been a suitable tool for global monitoring of new SARS-
76 CoV-2 cases. Currently, most pipelines for WGS rely on upper respiratory tract clinical diagnostic
77 samples with high viral loads [22,23]. However, antigen tests use anterior nasal (AN) swabs. NP
78 and AN swabs differ in the location from which specimen is derived from the patient [24–26].
79 Additionally, NP swabs are stored in up to 3 milliliters (mL) of viral transport media or buffered
80 saline solutions whereas AN swabs are inserted into an antigen card with only a few drops of
81 proprietary extraction buffer [16,25]. Finally, after collection, samples in viral transport media are
82 stored in freezers; where antigen cards may be stored at a range of temperatures. All of these
83 pre-analytical factors present concerns regarding the quality of specimen to be used for whole-
84 genome sequencing.

85 **Sequencing considerations**

86 To continue whole-genome sequences at institutions that have adopted antigen testing,
87 communication with clinicians is required to minimize pre-analytical factors that may lead to
88 sample degradation or discarding of samples. Institutions that choose to adopt antigen-based
89 whole genome sequence pipelines must work with clinicians and institutional review boards
90 (IRBs) to ensure that clinical specimens are retained for genome surveillance purposes. Clinical
91 researchers must also work with clinicians to ensure proper storage of antigen cards prior to
92 transportation to the sequencing laboratory.

93 Here, we tested various collection and storage parameters to optimize sample preparation for
94 SARS-CoV-2 whole genome sequencing from Ag-cards. We demonstrate that it is possible to
95 produce high quality genomic surveillance data from antigen-derived AN swabs. Specifically, we
96 validated PCR-based whole genome sequencing from AN swabs from the BinaxNOW™ COVID-
97 19 Ag Card (Abbott Diagnostics Scarborough).

98

99 Results

100 Workflow

101 Our optimized workflow, shows how de-identified, excess clinical specimens of positive
102 BinaxNOW™ COVID-19 Ag Cards are processed (**Figure 1**). Per CDC [18,27] and BMBL 6th
103 Edition [28] guidelines for handling SARS-CoV-2, the antigen cards are handled in a biosafety
104 cabinet in a biosafety level 2 (BSL2) room. Flocked swabs are removed from the antigen card
105 and placed into 500 μ L of DNA/RNA Shield in a 15 mL conical tube. Swabs are then broken at
106 the breakpoint, the tube cap securely fastened, and the sample vortexed vigorously for 15-30
107 seconds. Samples are stored at 4°C until RNA extraction. Viral load is determined using a
108 modified version of the CDC research use only (ROU) real-time RT-PCR assay, which targets the
109 viral nucleocapsid (CDC 2019-nCoV N1) and human RNase P (RP). Samples with an N1 cycle
110 threshold (C_T) less than 25 have sufficient quantity of SARS-CoV-2 RNA for sequencing library
111 preparation (Paragon Genomics CleanPlex Flex SARS-CoV-2 Panel). Prepared libraries are
112 checked using fragment analysis and a library quality ratio score is calculated as previously
113 described [29]. Briefly, quality ratio scores are calculated by dividing the concentration [ng/ μ L] of
114 target amplicons (fragments 250 base pairs (bp) to 350 bp) by the concentration of nonspecific
115 bands (50 base pairs (bp) to 190 bps). Samples with a quality score greater than or equal to one
116 are sequenced using Illumina's MiSeq or NextSeq500 systems. Finally, sequence data is
117 processed through a user-defined bioinformatics pipeline.

118
119 **Figure 1.** Workflow. (A) BinaxNOW™ antigen cards are run per manufacturer guidelines. (B-C)
120 Swabs are removed, placed in 500 μ L DNA/RNA shield, broken at the breakpoint, capped and
121 vortexed in a biosafety cabinet (23). (D) RNA is extracted. (E) RT-PCR is used to measure viral
122 load as N1 C_T . (F) Library preparations are made for samples with C_T values less than 25. (G)
123 Fragment analysis is used to check library quality and (H) samples with a quality score of equal

124 to or greater than 1 are sequenced. (I) An in-house bioinformatics pipeline is used to process
125 sequence data.

126 **Sample Preparation Optimization**

127 To optimize the sample collection and preparation methods, we utilized a previously sequenced
128 SARS-CoV-2 positive NP specimen with an N1 C_T of 12.28 (#5195) (**Fig 2**). First, we examined
129 the potential for sample loss and degradation due to (1) exposure to the BinaxNOW™ proprietary
130 extraction buffer and (2) storage conditions (**Fig 2A**). In this, and every following experiment, we
131 included a standardized positive control, water extraction, and no template control. The positive
132 control result is shown; however, the water extraction and template controls are not shown, due
133 to their expected and observed lack of amplification. A BinaxNOW™ COVID-19 Ag Card swab
134 was dipped into NP specimen # 5195 and then placed into 500 μ L DNA/RNA shield (*swab, no Ag*
135 *test*). For comparison, a second swab dipped into the same NP specimen, run through the antigen
136 test for 15 min per manufacturer's instructions, and then placed into DNA/RNA shield (*swab*). The
137 N1 C_T of the "swab, no Ag test" sample was 15.75 while the N1 C_T of the "swab" sample was
138 15.82, indicating that little to no viral RNA was lost after 15 min exposure to the Ag-card extraction
139 buffer. To test if prolonged storage of antigen cards might affect sample yield, a third swab was
140 dipped into the NP specimen, run through the antigen test, and the whole card was stored at 4°C
141 for 2 hours before the swab was placed in DNA/RNA Shield (*swab & storage*). Again, RT-PCR
142 results revealed that there was no sample degradation, as observed through N1 C_T values of
143 15.82 (*swab*) and 15.60 (*swab & storage*). PCR-amplicon sequencing libraries were then
144 prepared for each sample using the Paragon Genomics CleanPlex Flex SARS-CoV-2 Panel. For
145 a library prep and sequencing control, we also prepared a library using commercially available
146 SARS-CoV-2 genomic RNA (ATCC # VR-1986D, SARS-Cov-2 Isolate USA-WA1/2020). Library
147 quality scores were calculated as previously described and samples were sequenced at 2x151
148 bp reads on the Illumina MiSeq system. N1 C_T , library quality ratio scores, 20X genome coverage

149 (20 or more reads mapped per nucleotide), and viral PANGO lineages are shown in **Figure 2B**.
150 As expected, the positive control VR-1986D was assigned to PANGO lineage A and all dipped
151 Ag-card specimens were assigned to PANGO lineage B.1, the same lineage assigned to NP
152 specimen 5195. IGV snapshots show that all samples map at greater than 99.5% at 20X coverage
153 across the genome (**Fig 2C**). Together these finding indicated that sample exposure to Ag-card
154 buffer and testing conditions do not impact the quality of RNA and subsequent sequencing steps.

155
156 **Figure 2.** Assay Development. (A) An NP specimen was used to evaluate the feasibility of
157 obtaining viral RNA from Ag-card derived specimens. RT-PCR was carried out on specimens
158 collected under each condition. (B) RT-PCR N1 and RP Ct values, sequence library quality
159 scores, and viral PANGO lineage assignments of antigen card specimens and reference NP
160 specimen #5195. (C) IGV screen shots of sample SARS-CoV-2 genome coverage. VR-1986D =
161 Positive Control Genomic RNA from SARS-Cov-2, Isolate USA-WA1/2020.

162

163 **Performance Comparison**

164 Given that we carried out our preliminary tests in a mock fashion by dipping swabs in a previously
165 tested NP specimen, we next utilized COVID-19 positive Ag-cards to test the viability of
166 sequencing from real specimens (excess clinical specimens collected under IRB-approved
167 protocol FWH20200103E). Seven completed SARS-CoV-2 positive BinaxNOW™ COVID-19 Ag
168 Cards were delivered to the lab and immediately processed as follows: Antigen cards were
169 disassembled and the AN swabs and positive line of the lateral flow strips were separately placed
170 into DNA/RNA shield, stored at 4°C for 48 hours, extracted, then amplified using RT-PCR (**Fig**
171 **3A**). We hypothesized that due to the nature of the lateral flow assay, viral RNA would be
172 concentrated on the positive line of the strip. We found that swabs slightly outperformed the
173 positive line by yielding higher viral loads in all samples. Specifically, swab N1 C_T values were,

174 on average, 1.57 C_Ts lower than the line (\pm 1.16 C_Ts) (p-value = 0.0116). Interestingly, host RNA
175 levels were significantly higher in the swabs: RP was detected in swab specimens 4.43 cycles
176 sooner than the line (\pm 1.30 C_Ts) (p-value = 0.0001). Thus, relative to host RNA, viral RNA is
177 enriched on the positive line. As we were able to detect comparable levels of viral RNA on swabs
178 and positive lines, we next prepared libraries from three samples with N1 C_T < 25 from both the
179 swab and positive line (**Fig 3B and 3C**). Regardless of the sample source, sequenced specimens
180 had 20x genome coverage (20 or more reads per nucleotide) of greater than or equal to 99%,
181 signifying that both the swab and positive line from antigen cards can be used for whole-genome
182 sequencing with no loss in coverage.

183
184 **Figure 3.** Sample source performance comparison. (A) SARS-CoV-2 positive BinaxNOW™
185 COVID-19 Ag Cards were used to evaluate which part of the card, swab or lateral flow positive
186 line, yielded the highest quantity and quality of viral RNA. Extracted RNA was tested for N1 and
187 RP levels using RT-PCR. The average N1 and RP C_T values are plotted. n = 7 cards. Statistical
188 analysis = Two-tailed, paired *t*-test, * p<0.05; *** p<0.0005 (B) N1 and RP Ct values, library quality
189 scores and PANGO lineage assignments. (C) IGV screen shots of SARS-CoV-2 genome
190 coverage.

191

192 Discussion

193 When the COVID-19 pandemic started, highly sensitive and specific real-time RT-PCR tests were
194 the first to be developed, quickly becoming the mainstay of diagnostic testing [30,31]. However,
195 RT-PCR tests require specialized kits, equipment, personnel, and laboratories. These factors lead
196 to slower turnaround times as compared to recently released rapid diagnostic tests - which can
197 be readily employed to screen populations such as basic military trainees. With more clinicians

198 and point-of-care testing sites adopting antigen-based SARS-CoV-2 tests, fewer RT-PCR
199 specimens may be available to support genomic surveillance of viral variants worldwide. To
200 facilitate future genomic surveillance efforts, we developed a workflow for SARS-CoV-2 whole-
201 genome sequencing from antigen-based test specimens (**Fig 1**). We were able to recover viral
202 RNA of sufficient quantity and quality for targeted sequencing of the SARS-CoV-2 genome (**Fig**
203 **2**). We found that the quality of genome sequences derived from Ag-test samples is comparable
204 to RNA isolated from NP swabs collected for RT-PCR (**Fig 2**). Furthermore, a comparison of
205 sample sources, antigen card swab vs. lateral flow assay (LFA) positive line, showed that viral
206 RNA from both sources can generate high quality sequencing libraries (**Fig 3**). For ease of use
207 and biosafety concerns, we recommend collecting the swab over the LFA positive line as both
208 specimen types produced comparable libraries.

209 Antigen card specimens present a few limitations when compared to NP swabs collected in viral
210 transport media (VTM). First, in the workflow presented here, antigen test swabs are stored in
211 500 μ L of DNA/RNA shield while NP swabs are stored in up to 3 mL of VTM. Multiple RNA
212 extractions can be carried out from VTM specimens after the initial round RT-PCR testing but,
213 antigen swab-derived viral RNA can only be extracted once. Next, variants with novel or
214 interesting mutations can be cultured from VTM; enabling downstream biochemical or viral
215 neutralization assays. In contrast, antigen tests immediately expose the specimen to an extraction
216 buffer which disrupts the viral membrane, releases viral RNA, and enables the presentation of
217 viral nucleocapsid antigens to anti-nucleocapsid antibodies on the LFA positive line. Thus,
218 viruses collected post antigen-test are most likely non-culturable, however we did not evaluate
219 cultivability.

220 Here we only attempted to sequence from the BinaxNOW™ antigen test, but other antigen tests
221 may also yield viable specimens for whole-genome sequencing. This work is a first step for future

222 studies examining the sequencing utility of specimens collected for other antigen or rapid
223 molecular tests.

224

225 **Materials and Methods**

226 **Specimen Acquisition**

227 The BinaxNOW™ COVID-19 Ag Card (Abbott) was used to test basic medical trainees for SARS-
228 CoV-2. Excess clinical specimens were de-identified, the entire card placed in a plastic biohazard
229 bag, and samples transferred to the Clinical Investigations and Research Support (CIRS)
230 laboratory. Excess clinical specimens were obtained under an institutional review board (IRB)
231 exempt protocol (IRB reference number FWH20200103E).

232 **Specimen Preparation**

233 The antigen card was disassembled in a biosafety cabinet. The swab was placed in a 15 mL
234 conical tube with 500 μ L DNA/RNA Shield (Zymo Research, Catalog #R1100) and stored at 4°C
235 until the RNA was extracted. The positive line of the LFA test strip was excised and placed in 500
236 μ L of DNA/RNA shield and stored in a 2 mL cryovial at 4°C until the RNA was extracted.

237 **RNA Extraction**

238 Samples were extracted using the EZ1 Virus Mini Kit v2.0 (Qiagen, Catalog # 955134), per the
239 manual. Briefly, 400 μ L of sample was extracted and eluted into 60 μ L AVE buffer (supplied in the
240 kit). The following controls were run with each extraction: a positive control – a nasopharyngeal
241 swab of SARS-CoV-2 diluted to achieve a C_T of approximately 25 - and a negative control
242 consisting of 200 μ L nuclease-free water and 200 μ L of DNA/RNA Shield. The extracted RNA
243 was frozen at -80°C or used immediately for RT-PCR.

244 **RT-PCR**

245 The following primers were utilized: N1 Forward, 5'-GACCCCAAATCAGCGAAAT-3', N1
246 Reverse, 5'-TCTGGTACTGCCAGTTGAATCTG-3', N1 FAM probe, 5'-
247 (FAM)ACCCCGCATTACGTTTGGTGGACC(3'-BHQ-1)-3', RP Forward, 5'-
248 AGATTTGGACCTGCGAGCG-3', RP Reverse, 5'-GAGCGGCTGTCTCCACAAGT-3', and RP
249 Cy5 Probe 5'-(Cy5)TTCTGACCTGAAGGCTCTGCGCG(3'-BHQ-3)-3'. 20 µL reactions (15 µL
250 master mix + 5 µL RNA) were prepared using TaqPath™ 1-Step Multiplex Master Mix (No ROX)
251 (ThermoFisher Cat. # A28523) and 20X primer/probe mix. The final primer concentrations per
252 reaction were: N1 Forward & Reverse Primers (400 nM), N1 Probe (200 nM), RF Forward &
253 Reverse Primers (200 nM), and RP Probe (100 nM). The plate was run on the QuantStudio 7
254 under the following conditions: 25°C for 2 min, 53°C for 10 min, 95°C for 2 min, and 45 cycles of
255 95°C for 3 sec then 60°C for 30 sec. Fluorescence was detected at the end of each 60°C cycle.

256 **Library Preparation and Sequencing**

257 Paragon Genomics' CleanPlex® FLEX SARS-CoV-2 Panel (Cat. 918014) for Illumina platforms
258 was used to prepare sequencing libraries (starting concentration of 10-50 ng RNA per sample).
259 As a positive control, sequencing libraries were also prepped for VR-1986D, Genomic RNA from
260 SARS-Related Coronavirus 2, Isolate USA-WA1/2020. Library quality and concentration was
261 assessed via fragment analysis using Advanced Analytics' High Sensitivity NGS Fragment
262 Analysis Kit (Cat. DNF-474-0500). Library quality ratio scores (QRS) were determined by dividing
263 the fragment analysis 250-350 bp peak concentration (ng/µL) by 50-190 bp peak concentration
264 (ng/µL): excellent (QRS >10), Good (QRS 1.0 – 10), Fair (QRS <1 and >0.5), Poor (QRS < 0.5).
265 Libraries with QRS > 1.0 were denatured and diluted to a final loading concentration of 10 pM
266 following the Illumina MiSeq System Denature and Dilute Libraries Guide (Document # 15039740
267 v10), and then sequenced on the MiSeq system at 2 x 151 bp using the MiSeq v3, (600 cycle) kit
268 (Illumina, Cat. MS-102-3003).

269 **Bioinformatics**

270 Illumina adaptor sequences were trimmed using the BaseSpace Onsite FASTQ Toolkit v1.0.0.
271 Adapter trimmed FASTQ files were aligned to the SARS-CoV-2 reference genome
272 (NC_045512.2) using Illumina's DRAGEN Bio-IT Platform. Primer sequences were removed
273 using the Linux environment fgbio toolkit (bcftools) and a tab delimited file with primer genomic
274 coordinates provided by Paragon Genomics. The DRAGEN was used to create variant call files
275 from primer trimmed BAM files and consensus FASTA files were created using the fgbio toolkit.
276 Genome coverage uniformity and mapping was visualized in IGV (BAM and VCF files).

277

278 **Acknowledgements**

279 The authors would like to thank the laboratories who provided the excess clinical specimens
280 used in this research.

281

282 **References**

- 283 1. Li X, Wang W, Zhao X, Zai J, Zhao Q, Li Y, et al. Transmission dynamics and evolutionary
284 history of 2019-nCoV. *J Med Virol.* 2020;92: 501–511. doi:10.1002/jmv.25701
- 285 2. Borges V, Alves MJ, Amicone M, Isidro J, Zé-Zé L, Duarte S, et al. Mutation rate of SARS-
286 CoV-2 and emergence of mutators during experimental evolution. *bioRxiv.* 2021;
287 2021.05.19.444774. doi:10.1101/2021.05.19.444774
- 288 3. van Dorp L, Richard D, Tan CCS, Shaw LP, Acman M, Balloux F. No evidence for increased
289 transmissibility from recurrent mutations in SARS-CoV-2. *Nature Communications.*
290 2020;11: 5986. doi:10.1038/s41467-020-19818-2

- 291 4. Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, et al. Sequence
292 Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the
293 Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of
294 Multiple Isolates of All Major Variants of Concern. *Am J Pathol.* 2021;191: 983–992.
295 doi:10.1016/j.ajpath.2021.03.004
- 296 5. Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. *Nature.*
297 2021;589: 337–338. doi:10.1038/d41586-021-00065-4
- 298 6. Coughlin SS, Yiğiter A, Xu H, Berman AE, Chen J. Early detection of change patterns in
299 COVID-19 incidence and the implementation of public health policies: A multi-national
300 study. *Public Health Pract (Oxf).* 2021;2: 100064. doi:10.1016/j.puhip.2020.100064
- 301 7. Tillett RL, Sevinsky JR, Hartley PD, Kerwin H, Crawford N, Gorzalski A, et al. Genomic
302 evidence for reinfection with SARS-CoV-2: a case study. *Lancet Infect Dis.* 2021;21: 52–
303 58. doi:10.1016/S1473-3099(20)30764-7
- 304 8. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral
305 Diseases, CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021 May. Available:
306 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>
- 307 9. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
308 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science.* 2021;372.
309 doi:10.1126/science.abg3055
- 310 10. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F, Simon V, et al. The E484K
311 mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing
312 activity of human convalescent and post-vaccination sera. *medRxiv.* 2021.
313 doi:10.1101/2021.01.26.21250543

- 314 11. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine
315 against the B.1.1.7 and B.1.351 Variants. *N Engl J Med.* 2021 [cited 29 May 2021].
316 doi:10.1056/NEJMc2104974
- 317 12. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Efficacy of NVX-
318 CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med.* 2021;384: 1899–
319 1909. doi:10.1056/NEJMoa2103055
- 320 13. Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: a rapid systematic review
321 of case reports and case series. *J Investig Med.* 2021. doi:10.1136/jim-2021-001853
- 322 14. Center for Devices and Radiological Health, FDA. In Vitro Diagnostics EUAs - Molecular
323 Diagnostic Tests for SARS-CoV-2. 2021 May. Available: [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2)
324 [devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2)
325 [devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2).
- 326 15. Lippi G, Simundic A-M, Plebani M. Potential preanalytical and analytical vulnerabilities in the
327 laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clin Chem Lab Med.*
328 2020;58: 1070–1076. doi:10.1515/cclm-2020-0285
- 329 16. Marcus JE, Frankel DN, Pawlak MT, Casey TM, Blackwell RS, Tran FV, et al. COVID-19
330 Monitoring and Response Among U.S. Air Force Basic Military Trainees - Texas, March-
331 April 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69: 685–688.
332 doi:10.15585/mmwr.mm6922e2
- 333 17. Office of the Commissioner, FDA. Coronavirus (COVID-19) Update: FDA Authorizes First
334 Antigen Test to Help in the Rapid Detection of the Virus That Causes COVID-19 in
335 Patients. 2020 May. Available: <https://www.fda.gov/news-events/press->

- 336 announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-
337 detection-virus-causes.
- 338 18. Centers for Disease Control and Prevention. Interim Guidance for Antigen Testing for
339 SARS-CoV-2. 2021 May. Available: [https://www.cdc.gov/coronavirus/2019-
340 ncov/lab/resources/antigen-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html)
- 341 19. Joint Base San Antonio. MEDCoE Adds Antigen Testing Lab to COVID-19 Mitigation
342 Strategy. 2021 Feb. Available: [https://www.jbsa.mil/News/News/Article/2481284/medcoe-
343 adds-antigen-testing-lab-to-covid-19-mitigation-strategy/.](https://www.jbsa.mil/News/News/Article/2481284/medcoe-adds-antigen-testing-lab-to-covid-19-mitigation-strategy/)
- 344 20. Kumar M, Iyer SS. ASSURED-SQVM diagnostics for COVID-19: addressing the why, when,
345 where, who, what and how of testing. *Expert Rev Mol Diagn.* 2021;21: 349–362.
346 doi:10.1080/14737159.2021.1902311
- 347 21. Rasmi Y, Li X, Khan J, Ozer T, Choi JR. Emerging point-of-care biosensors for rapid
348 diagnosis of COVID-19: current progress, challenges, and future prospects. *Anal Bioanal
349 Chem.* 2021; 1–23. doi:10.1007/s00216-021-03377-6
- 350 22. Chiara M, D’Erchia AM, Gissi C, Manzari C, Parisi A, Resta N, et al. Next generation
351 sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities. *Brief
352 Bioinform.* 2021;22: 616–630. doi:10.1093/bib/bbaa297
- 353 23. World Health Organization. Genomic sequencing of SARS-CoV-2: a guide to
354 implementation for maximum impact on public health. WHO; 2021 Jan. Available:
355 <https://www.who.int/publications/i/item/9789240018440>

- 356 24. Food and Drug Administration. BioFire COVID-19 Test: Instructions for Use under an
357 Emergency Use Authorization (EUA) Only. 2020. Available:
358 <https://www.fda.gov/media/136353/download>
- 359 25. Food and Drug Administration. BINAXNOW COVID-19 AG CARD (PN 195-000) –
360 INSTRUCTIONS FOR USE. 2020. Available: <https://www.fda.gov/media/141570/download>
- 361 26. Ito Y. Clinical Diagnosis of Influenza. *Methods in molecular biology*. 2018;1836: 23–31.
- 362 27. Centers for Disease Control and Prevention. Interim Laboratory Biosafety Guidelines for
363 Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-
364 19). Available: [https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-](https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html)
365 [guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html).
- 366 28. DHHS, CDC & NIH. Biosafety in Microbiological and Biomedical Laboratories, 6th edn. (US
367 Government Printing Office, Washington, DC, June 2020).
368 <https://www.cdc.gov/labs/BMBL.html>. Available: <https://www.cdc.gov/labs/BMBL.html>
- 369 29. Nazario-Toole AE, Xia H, Gibbons TF. Whole-genome Sequencing of SARS-CoV-2: Using
370 Phylogeny and Structural Modeling to Contextualize Local Viral Evolution. *Military*
371 *Medicine*. 2021 [cited 29 May 2021]. doi:10.1093/milmed/usab031
- 372 30. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and
373 Probes. Available: [https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)
374 [probes.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html)
- 375 31. Kevadiya BD, Machhi J, Herskovitz J, Oleynikov MD, Blomberg WR, Bajwa N, et al.
376 Diagnostics for SARS-CoV-2 infections. *Nature Materials*. 2021;20: 593–605.
377 doi:10.1038/s41563-020-00906-z





Figure 1. Workflow. (A) BinaxNOW™ antigen cards are run per manufacturer guidelines. (B-C) Swabs are removed, placed in 500 μ L DNA/RNA shield, broken at the breakpoint, capped, and vortexed in a biosafety cabinet (23). (D) RNA is extracted. (E) RT-PCR is used to measure viral load as N1 C_T . (F) Library preparations are made for samples with C_T values less than 25. (G) Fragment analysis is used to check library quality and (H) samples with a quality score of equal to or greater than 1 are sequenced. (I) An in-house bioinformatics pipeline is used to process sequence data.

A C_T Values of Mock Ag-card Testing



B

Sample	N1 C_T	RP C_T	Library Score	Parental PANGO
Swab, no Ag test	15.75	25.41	5.29	B.1
Swab	15.82	24.75	5.79	B.1
Swab & storage	15.60	23.80	4.09	B.1
#5195 (VTM)	12.28	23.20	3.03	B.1

C





Figure 2. Assay Development. (A) An NP specimen was used to evaluate the feasibility of obtaining viral RNA from Ag-card derived specimens. RT-PCR was carried out on specimens collected under each condition. (B) RT-PCR N1 and RP C_T values, sequence library quality scores, and viral PANGO lineage assignments of antigen card specimens and reference NP specimen #5195 (C) IGV screen shots of sample SARS-CoV-2 genome coverage. VR-1986D = Positive Control Genomic RNA from SARS-Cov-2, Isolate USA-WA1/2020.



B

Sample Prep	N1 C _T	RP C _T	Library Score	PANGO
Swab A	18.16	21.89	35.99	B.1.1.7
Line A	21.31	27.38	19.13	B.1.1.7
Swab B	18.76	23.25	16.88	B.1.1.7
Line B	18.88	28.17	28.72	B.1.1.7
Swab C	21.04	22.97	8.86	B.1.1.7
Line C	22.51	26.95	6.29	B.1.1.7




Figure 3. Sample source performance comparison. (A) SARS-CoV-2 positive BinaxNOW™ COVID-19 Ag Cards were used to evaluate which part of the card, swab or lateral flow strip positive line, yielded the highest quantity and quality of viral RNA. Extracted RNA was tested for N1 and RP levels using RT-PCR. The average N1 and RP C_T values are plotted. n = 7 cards. Statistical analysis = Two-tailed, paired t-test, * p<0.05; *** p<0.0005 (B) N1 and RP C_T values, library quality scores and PANGO lineage assignments. (C) IGV screen shots of SARS-CoV-2 genome coverage.